Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger

Amid Continued Obesity Lag

The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.    

Scale made of rocks with equal weight of rocks on each side of scale, representing balance
Ozempic Sales Helped Balance Out Wegovy Troubles • Source: Shutterstock

Novo Nordisk A/S is focusing on novel diabetes R&D as its blockbuster drug Ozempic faces emerging competition, even as Ozempic sales made up for the firm’s struggling obesity franchise during the second quarter.

While the Danish firm grapples with manufacturing issues for its highly in-demand obesity drug Wegovy (semaglutide injection 2.4mg), its older...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip